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Abstract:
Introduction:
Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million
people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and
hepatocellular carcinoma.
Explanation:
Epidemiological studies have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of
hepatocellular carcinoma (HCC), mainly through chronic inflammation, cell deaths, and proliferation. Despite the new direct-acting
antiviral drugs (DAA’s) being able to clear the HCV, HCC recurrence rate in these patients is still observed.
Conclusion:
In this review we highlighted some aspects that could be involved in the onset of HCV-induced HCC such as immune system, viral
factors and host genetics factors.
Moreover, we focused on some of the last reports about the effects of DAA’s on the HCV clearance and their potential implications
in HCC recurrence.
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1. INTRODUCTION
Hepatocellular carcinoma (HCC), also known as malignant hepatoma, is a primary malignant tumor of the liver
arising from the liver cells (hepatocytes) [1].
Amongst the most common tumors worldwide [2], it occurs predominantly in patients with underlying chronic liver
disease and cirrhosis.
In  the  United  States,  HCC  is  the  ninth  leading  cause  of  cancer  deaths  [3].  Despite  advances  in  prevention
techniques, screening, and new technologies in both diagnosis and treatment, incidence and mortality continue to rise
(662,000 deaths worldwide per year) [2].
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HCC occurs  more  often  in  males  than females  (ratio  2,4:1)  and it  is  common between the  age  of  30 to  50 [2],
peaking  at  approximately  70  years  of  age  and  with  a  higher  incidence  in  Eastern  and  Southern  Asia,  Middle  and
Western Africa, Melanesia, and Micronesia/Polynesia [3].
1.1. Risk Factors
The distribution of risk factors in patients with HCC depends on the ethnic group, race or geographical region. The
most  common risk  factors  are:  infection  with  Hepatitis  B virus  (HBV) or  Hepatitis  C virus  (HCV),  alcoholic  liver
diseases,  Non-Alcoholic  Fatty  Liver  (NAFLD),  Non-Alcoholic  Steatohepatitis  (NASH)  and  aflatoxins  [1].  Less
common causes include sex and metabolic and genetic diseases such as diabetes mellitus, obesity, hemochromatosis and
Wilson’s disease.
The above-mentioned risk factors often lead to the formation and progression of cirrhosis, which is present in 80 to
90% of patients with hepatocellular carcinoma.
In  the  developing  world,  viral  hepatitis  (primarily  hepatitis  B)  continues  to  represent  a  major  risk  for  the
development of HCC. Worldwide, chronic HBV infection accounts for approximately 50% of all cases of hepatocellular
carcinoma and virtually all childhood cases.
The World Health Organization estimates that every year 3–4 million people get infected with hepatitis C virus
(HCV)  worldwide.  Whereas  130–170  millions  of  chronically  infected  individuals  are  at  risk  of  developing  liver
Cirrhosis, Hepatocellular Carcinoma (HCC), or both. These infections induce over 350 thousand deaths per annum, but
the manifestation varies widely with geographical deviations. The prevalence is as low as 0.1–1% in northern Europe to
2.5–3.5% in  southern  Europe.  Amongst  the  most  affected  countries  is  Egypt,  with  22% of  its  population  infected,
followed by Pakistan and China, with more than 3% of their population infected with HCV [4].
Hepatitis C virus infection was first suspected in the 1970s, when most blood transfusion infections were associated
with either hepatitis A or hepatitis B virus. This new type of blood-transmitted hepatitis was then called “non-A, non-B”
hepatitis.
The genome of HCV was identified in 1989, and the name hepatitis C was subsequently applied to human infection
caused by this single-strand Ribonucleic Acid (RNA) virus of positive polarity [5].
Although its origin remains unclear, HCV might have originated from zoonotic sources such as non-human primates
(e.g. monkeys, apes) and mammals (e.g. dogs, horses) [6].
Hepatitis C virus belongs to the Hepacivirus genus, Flaviviridae family, and exhibits high genetic variability. There
are  seven  different  genotypes,  and  more  than  70  subtypes  [5]  and  their  global  prevalence  is  unequally  distributed.
Amongst  7  HCV  genotypes,  genotype  1  and  3  account  respectively  for  46.2  and  30.1%  of  the  global  infections;
genotypes 2, 4, and 6 are present in approximately 22.8% of HCV infections and genotype 5 represents the remaining
less than 1%; genotype 7 has been identified so far in very few patients originating from Central Africa [6].
A single HCV particle is approximately 68 nm in diameter [6].
A lipid bilayer envelope surrounds a capsid. The viral envelope bears E1 and E2 glycoprotein complex that plays a
fundamental role in viral and host cell interaction [4].
Viral genome, comprised of 9600 nucleotides, encodes a 3000 aminoacid polyprotein, which is post-translationally
modified into three structural proteins and six non-structural proteins. Structural proteins, Core, E1, and E2, create the
capsid and the envelope, while non-structural proteins, NS2, NS3, NS4A, NS4B, NS5A, and NS5B, are the building
blocks for the particle and play a vital role as genome replicating proteins [4].
Alcohol abuse is an important risk factor for development accounting for 40%–50% of all HCC cases in Europe.
The relationship between alcohol and liver disease correlates with the amount of alcohol consumed over a lifetime, with
heavy alcohol use rather than social drinking being the main risk of HCC.
Chronic diseases such as diabetes mellitus and obesity increase the risk of HCC. Diabetes mellitus directly affects
the liver because of the essential role the liver plays in glucose metabolism.
Hyperinsulinemia has been associated with a  threefold increased risk of  HCC. It  is  believed that  the pleotropic
effects of insulin which regulate the anti-inflammatory cascade and other pathways inducing cellular proliferation, play
a role in carcinogenesis.
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It is well established that obesity is associated with many hepatobiliary diseases, including nonalcoholic fatty liver
disease (NAFLD), steatosis, and cryptogenic cirrhosis, all of which can lead to HCC.
Gender may also play a role in the development (growth, evolution, production) of Hepatoma, occurring more often
in males, with a ratio of 2:1– 4:1 . Males are more likely to get infected with viral hepatitis, consume greater quantities
of alcohol,  smoke cigarettes,  and have a higher body mass index than women. Higher testosterone levels  may also
increase the incidence in males and the formation of liver adenomas.
Aflatoxins, metabolites of the fungi Aspergillus flavus and Aspergillus parasiticus are frequent contaminants of
food, and are associated with a high rate of HCC development [7]. The risk of HCC with aflatoxin depends on the
amount and duration of exposure. Aflatoxin exerts a synergistic effect on hepatitis B- and C-induced liver cancer, with
the risk being 30 times greater with chronic hepatitis B plus aflatoxin exposure than with aflatoxin exposure alone [3,
8].
Metabolic and genetic diseases associated with HCC include hemochromatosis, Wilson’s disease, alfa-1 antitrypsin
disease, tyrosinemia, glycogen-storage disease types I and II, and porphyrias. Other risk factors may include cigarette
smoke, associated with a significant increase in the development of HCC [3].
1.2. Pathogenesis
As  a  blood-borne  virus,  HCV  can  be  transmitted  over  blood  transfusions,  needle  sharing,  sexual  contacts,  or
maternal transmission. Although HCV can circulate in many human organs, it especially infects hepatocytes in the liver
and evades the host innate and adaptive immune system. With an incubation period of 2 to 12 weeks, HCV infection
begins with an acute phase that usually goes undiagnosed, during which symptomatic infections (10% to 15%) and
asymptomatic infections (85% to 90%) are observed. Approximately, 25% to 52% of symptomatic infections and 10%
to 15% of asymptomatic infections undertake spontaneous viral clearance, indicating that HCV is cleared from HCV-
infected patients by specific immune responses. If not cleared, acute HCV evolves into chronic HCV. Without proper
treatment, patients with chronic HCV are threatened by serious complications such as cirrhosis, liver cancer, and liver
failure. Liver damage is a consequence of long-lasting inflammation when host immune responses are activated to fight
HCV infections [6].
Hepatocarcinogenesis is a highly complex multistep process: it starts from hepatic stem cells or mature hepatocytes
under the condition of chronic liver disease initiated by oxidative stress, chronic inflammation and cell death followed
by uncontrolled proliferation/restricted regeneration and permanent liver remodeling.
In  response  to  cytokine  stimulation  caused  by  hepatocyte  injury,  extensive  compensatory  cell  proliferation  and
regeneration take place, followed by fibrosis and cirrhosis, particularly driven by the synthesis of extracellular matrix
components from hepatic stellate cells. Finally, in this carcinogenic environment, hyperplastic and dysplastic nodules
form and normal liver tissue turns cancerous. The molecular pathogenesis of HCC involves different genetic/epigenetic
aberrations and alterations in multiple signaling pathways leading to the known heterogeneity of the disease concerning
its biologic and clinical behavior [1].
2. IMMUNITY
In  patients  persistently  infected  with  HCV,  chronic  inflammation  resulting  from  the  immune  response  against
infected hepatocytes typically lasts many decades and it frequently leads to progressive liver disease that ranges from
inflammation to severe fibrosis, that can culminate in hepatic cirrhosis and Hepatocellular Carcinoma (HCC) [9].
A variety of PRRs (Pattern Recognition Receptors) sense viruses as foreign invaders within the host cell through
specific PAMP (Pathogen Associated Molecular Patterns) recognition to activate innate immune signalling [10]. The 3
major classes of PRRs include Toll-like receptors (TLRs), RIG-1-like receptors (RLRs), and nucleotide oligomerization
domain (NOD)-like receptors (NLRs) [11].
NS5B,  the  HCV RNA-dependent  polymerase,  can  activate  innate  immune  signalling  through  dsRNAs  that  are
transcribed from nonspecific cellular templates. Both TLR3 and RIG-1 can trigger cellular responses to RNA produced
by NS5B, but Vegna et al. showed that NS5B induces and activates NOD1, a receptor classically associated with a
response  to  bacterial  infection,  that  has  as  downstream  effector  RIPK2,  which  leads  to  MAPK  activation,  type  I
interferon production and NF-κB-dependent signalling [9]. The persistent inflammatory response observed in the liver
of  HCV-positive  patients  thus  impacts  many  aspects  of  HCV-associated  pathology,  including  HCC,  by  creating  a
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favorable environment for disease progression [9].
Recently, Lopes et al. [12] have shown that TLRs are closely related to carcinogenesis. Also myeloid differentiation
factor  88  (MyD88),  the  TLR  and  interleukin  (IL)-1  receptor  adaptor  molecule,  has  been  linked  to  tumorigenesis.
Kinowaki et al. [13] examined the expression of MyD88 in human HCC tissues, finding that attenuated expression of
MyD88 in HCC tissues is associated with tumor progression. This was in contrast with other recent reports [14 - 16].
Tumor necrosis factor-α-induced protein-8 like-2 (TIPE2) is a newly identified protein essential for the maintenance
of immune homeostasis and for tumorigenesis suppression. Recently, a study showed that another HCV protein, NS5B,
can lead to hepatocellular carcinogenesis by promoting TIPE2 degradation [17].
Golgi  protein  73  (GP73)  is  a  serum biomarker  for  liver  disease  and  HCC with  high  specificity  and  sensitivity.
However, the mechanism underlying GP73 regulating HCV infection is poorly understood. Zhang et al. [18] discovered
that GP73 acts as a negative regulator of host innate immunity: it binds directly to mitochondrial antiviral signaling
protein  (MAVS)  and  TNF  receptor-associated  factor  6  (TRAF6)  to  promote  their  degradation,  which  result  in  the
repression of host innate immunity and facilitation of HCV infection.
Persistent infection by hepatitis C virus (HCV) represents one of the main risk factors for HCC and has been shown
to  impair  NK-cell  response,  mainly  exerting  a  suppressive  function  that  might  play  a  role  in  tumor  promotion  or
progression [19].
With  the  aim to  investigate  the  phenotype  and  function  of  peripheral  blood  NK in  HCV-linked  HCC and  their
possible prognostic implications, Cariani et al. [19] evaluated a cohort of patients with HCV-related HCC: they found a
decreased expression of inhibitory receptor NKG2A and of molecules linked to effector function (CD3z, perforin) in
peripheral blood NK-cells from HCC patients. The study thus supports prognostic relevance of NK-cell phenotype and
function in HCC.
3. HCV AND HCC: WHAT ABOUT GENETICS?
There are 3 IFN-lambda genes that encode 3 distinct but highly related proteins denoted as IFN-lambda1, -lambda2,
and  -lambda3.  These  proteins  are  also  known  as  interleukin-29  (IL-29),  IL-28A,  and  IL-28B,  respectively.  Only
recently IFN lambda 4, a new member of the family, was discovered. These cytokines comprise the type III subset of
IFNs  [20].  In  HCV  infected  patients,  genetic  variations  in  the  IFNλ  locus  are  associated  with  spontaneous  viral
clearance and type I IFN-based treatment success [21, 22]. Three major SNP near IFNL3 and INFL4 genes correlate
with  HCV  treatment  response:  rs12979860(C/T),  rs8099917(T/G)  and  rs368234815(TT/ΔG)  [23].  The  molecular
mechanisms that control the association between IFNλ polymorphisms and the clinical outcome of HCV infection still
remain unclear.
In 2015, a study demonstrated a correlation between the rs8099917 SNP and IL28B serum levels, while other SNPs,
including rs12979860 failed to show a similar correlation. They observed that the T-allele of rs8099917 was correlated
with  reduced  IL28B  serum  levels.  Also,  they  found  that  IL28B  serum  levels  had  significant  correlation  with  the
different outcomes of HCV infection, especially among patients suffering from cirrhosis and HCC, where IL28 serum
level tend to increase with the progression of the disease, but even if IL28B variants might play a significant role in
HCV infection, they may not be considered as risk factors in the progression of the infection to advanced stages such as
HCC. However, further investigations are needed to explain the effect of IL28B levels on disease progression [24].
TLRs are a group of molecules that are essential for the innate immune response against pathogens. De Re et al. in
2016  investigated  the  hypothesis  of  a  functional  connection  between  IL28B  and  toll-like  receptor  2,  a  pattern
recognition receptor that has specific polymorphism associated with hepatocarcinogenesis. This study emphasizes that
both  TLR2  and  IL28B  polymorphism  may  have  a  role  in  directing  HCV-progression  towards  hepatic  diseases:  in
particular, the presence of IL28B-C allele in homozygosity has a potential protective effect towards chronic infection
and liver diseases, but the simultaneous presence of at least one TLR2-del allele abolished this effect; the TLR2-del/del
state appeared also closely linked with HCC condition [25].
Lately, Yuan et al. described the TLR3 mediated antitumor activities towards HCC. In 2017 a study of Al-Anazi
investigated the influence of genetic variants within TLR3 with the purpose to determine the association with HCV
infection and HCV-related liver damage that results in cirrhosis and HCC. They found that rs78726532 was strongly
associated with HCV infection. Moreover, the rs78726532 GG genotype had a protective role for HCV infection. Three
more TLR3 SNPs were associated with HCV related end stage liver disease progression (liver cirrhosis and HCC) [26].
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In 2014, Mc Farland et al. reported the identification of a functional polymorphism (rs4803217) located in the 3′
untranslated region (3′ UTR) of the IFNL3 mRNA that dictates transcript stability. This polymorphism influences AU-
rich element-mediated decay as  well  as  the  binding of  HCV-induced microRNAs during infection.  Together,  these
pathways mediate robust repression of the unfavorable IFNL3 genotype [27]. More recently, another study compared
rs4803217 to IFNL4-ΔG/TT, a functional variant that controls generation of the IFNL4 protein, showing evidence that
the IFNL4- ΔG allele is a primary variant for impaired clearance of HCV [28].
Another study has recently shown the association between SNPs in 3 genes involved in early immune response
against HCV and the risk of progressive liver disease: low molecular mass polypeptide 7 (LMP-7), interleukin 28B
(IL28B)  and  2’-5’oligoadenylate  synthetase  1  (OAS1).  In  particular,  SNPs  in  LMP-7  and  IL28B  rs12979860  are
associated with the development of HCC [29].
These findings highlight the importance of host genetic factors in determining the early stages of HCV infection and
the development of HCV-associated HCV diseases.
4. VIRAL AND NON-VIRAL FACTORS INVOLVED IN HCV-RELATED HCC
The escape from the immune system may represent one of the mechanisms by which HCV establishes persistent
infection  and  which  contributes  to  the  maintenance  and  development  of  cancer.  Epidemiological  studies  on  the
association between hepatitis C virus infection and Hepatocellular carcinoma (HCC) development have begun in rapid
succession after the development of the first detection test specific antibody [30]. A direct role in inducing HCC was
highlighted in transgenic mice for core expression in which the induction of hepatic carcinoma is accelerated [31].
Direct  and  indirect  pathways  of  carcinogenesis  are  responsible  for  HCC  development  and  understanding  of  these
pathways  will  be  key  to  devising  new  treatment  strategies.  The  most  important  mechanisms  are:  direct  pathways
involving the HCV core protein, indirect injury from oxidative stress and steatosis leading to hepatocyte death, and
micro RNA (mi-RNA) instability. The possible mechanisms for HCC induction by the HCV virus are, however, little
known being an RNA virus in which the replicative cycle, which occurs in the cytoplasm, a DNA phase is not present
or the possibility of viral integrals or viral oncogenes is known [32]. It is believed that an important role is given by
viral persistence in immune stimulus incessant exercise. Consequently, the HCV core protein plays a pivotal role in the
development of direct mechanisms of HCC; in fact, the core deregulates the pathways by inhibiting retinoblastoma
protein (RB) and p53 tumor suppressor [33]. Furthermore, HCV NS5 inhibits the apoptosis regulators BCL-2, and it is
the cause of abnormal activation of signaling pathways that promote growth, such as Wnt/beta catenin and mammalian
target of rapamycin (mTOR) [34]. Further, hypotheses are related to a possible indirect role of some viral proteins, in
particular core protein and NS5. HCV core protein interacts with different routes of intracellular signal transduction
(TNF-α, NF-kB, activation of the path induced by oxidative stress: kinase MAPK, JNK / SAPK); inhibits and induces
apoptosis Fas- and TNF-α mediated thus contributing to increased survival or increased proliferation of hepatocytes
[35]. The research group of Dr. Conti highlighted, during HCV life cycle with the help of a HCV infection model, a
functional interaction between Small Heterodimer Protein 1 (SHP1), a steatogenic protein, and HCV NS5A protein.
They demonstrated that  SHP1 silencing (siSHP1) reversed the  pro-oncogenic  effects  of  HCV infection,  inducing a
significant decrease in liver lipid accumulation and in NS5A protein expression. Moreover, siSHP1 causes a strong
modulation  of  some  genes  involved  in  HCV-related  EMT,  such  as:  HNF4,  a  central  regulators  of  hepatocyte
differentiation, E-Cadherin, SNAILs. This data suggest that SHP1 has been shown not only to be strictly connected to
the pathogenesis  of  HCV-related liver  steatosis,  but  also to its  progression towards liver  transformation [36].  HCC
microarray analysis suggested that some clusters of genes involved in growth cells are over-regulated (PCNA, members
of the cycling family: CDC20, CDK4, Myb) while other genes of the Wnt catenin-β family and metalloproteinases were
modulated in the expression of HCC [37].
The expression of miRNAs in hepatic tissue is related to the pathogenesis of liver disease, including, hepatocellular
carcinoma. Different mi-RNA are downregulated in HCC and need more studies to evaluate the real role of this RNA
[38 - 40]. These and other papers indicate that miRNAs may be biomarkers for the evaluation of HCC, but candidate
miRNAs are different. Further research is definitely required in future works.
5. HCV AND HCC: ANY RELATIONSHIP WITH DAAS?
The advent of novel direct-acting antivirals (DAAs) has totally changed the landscape of HCV therapy. In fact,
HCV infection cure rate is estimated at around 90%, with a sustained virological response (SVR) of around 95-97%
[41,  42].  These  results  have  raised  the  hope  of  an  improvement  in  disease  severity.  One  of  the  main  expectations
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following DAA treatment is not only to eradicate the virus, but to improve liver function too, such as cirrhosis, fibrosis
and HCC. In particular, the reduction of inflammation can lead to a decrease of cirrhosis and HCC.
Indeed, in the past, Interferon (IFN) based therapies have demonstrated that this treatment resulted in an increased
HCV  clearance  and  that  SVR  had  reduced  liver  fibrosis,  cirrhosis  and  HCC  [43,  44].  These  data  are  even  more
consistent considering the anti-tumor and anti-proliferative effects of IFN [45]. Nevertheless, given the adverse effects
of IFN and ribavirin, a new class of direct-acting antivirals drugs has been introduced. DAAs are antiviral drugs that
impact HCV replication at different stages, such as protein assembly or polymerase activity.
But what’s the real effect of DAAs on HCC in HCV populations? Not much data on the role of DAAs-induced
HCV eradication  in  HCC occurrence  are  available.  Recently,  some  controversial  data  have  been  published  on  the
relationship between HCC recurrence and DAAs treatment in HCV spanish population. In fact, Reig et al show that
despite a high rate of SVR after treatment with DAAs, an elevated number of HCC recurrence has been observed in
their cohort. In particular, they included 55 HCV patients, with a complete radiological response after a prior history of
HCC who received DAAs, as a final study population and they observed a radiologic tumor recurrence of (27.6%) (16
of 55 patients) [46]. The observed a very close time between DAAs treatment and cancer recurrence (median time 3,5
months). In their opinion, these data raise a concern about the benefit of DAAs on HCV patients with a prior HCC
history.
Another study of Conti et al. found that, during the 24 weeks follow-up evaluation, HCC was detected in 26 of 344
HCV patients (7.6%). In particular, HCC developed in 17 of the 59 patients with a prior history of HCC (28.81%), and
in  9  of  the  285  (3.2%)  who did  not  expertise  cancer  in  their  life  [47].  In  both  these  studies  a  high  rate  of  SVR is
observed, confirming real effectiveness of DAAs against HCV infection. When Conti et al. compared these data with
HCC recurrence in HCV untreated population, they found a similar rate of cancer development, suggesting that it is not
possible to affirm that DAAs treatment is involved in HCC.
Another study by The ANRS collaborative study group on hepatocellular carcinoma, in France, reported that no
increased risk of HCC recurrence in HCV populations has been observed following DAAs treatment [48].
Furthermore, the HCC recurrence found by Conti  et al.  is  similar to that found in an Italian study in which the
authors indicate that HCC recurrence after 1 year from the surgical resection of the tumor is around 20% [49].
One  of  the  most  important  concerns  is  to  understand  why  a  sudden  HCC  recurrence  after  DAAs  treatment  is
observed.
An explanation of these results is not yet reached but one of the main hypotheses is that following DAAs treatment
a perturbation of the immune system occurs.
In fact, it’s been hypothesized that changes in pro and anti-tumor signals after DAAs treatment could impact on the
HCC recurrence. For example, DAAs therapy-induced SVR could cause the reduction of Natural Killer (NK) cells and
their role in immuno surveillance, enhancing the growth of the undetected tumor [50]. This phenomenon is unlikely in
HCV patients treated with IFN, because of the immuno modulatory and anti-proliferative effect of this cytokine [51].
Consistent with this hypothesis, an Italian study speculated that drugs could induce HCC recurrence through an
increase in tumor cells dissemination. In particular, Villani et al. found an increase in vascular endothelial growth factor
(VEGF) levels during DAAs therapy, while they normalized within 12 weeks at the end of therapy [52]. The serum of
these patients, also, had angiogenic properties, when tested in an in vitro cells stimulation assay [52]. VEGF is a critical
factor  in  angiogenesis,  that  is  mainly  responsible  for  tumor  dissemination  and  it  seems  to  correlate  with  a  rapid
development and recurrence of HCC [53]. The effects of DAAs on inflammatory pattern and on the immune system
seem to be related to the onset of HCC in HCV population. Other studies reported changes in the immune system and
the reduction of IFN producing cells following DAAs treatment [50, 54], suggesting that DAAs can reset HCV viral
load but could be involved in modifying the inflammatory pattern and the immuno surveillance against HCC.
6. DAA-RAMS OCCURRENCE AND HCC DEVELOPMENT
An important issue to face is the onset of DAAs related- resistance associated mutations (RAMs). Treatment with
DAAs that target the HCV protease NS3/4A, NS5A and the NS5B polymerase proteins can lead to more than 90% SVR
[55].
HCV has higher diversity and variability in its genome compared to other viruses. During its replicative cycle, a lot
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of mutations occurs in the genome, creating a pool of virus variants termed “quasispecies” [56].
RAMs are often used to describe the amino acid substitutions that reduce the susceptibility of a virus to a drug.
Viral resistance after DAAs administrations occurs when some viral variants with reduced susceptibility to drugs are
selected and replicate [57]. Resistance of HCV to DAAs is determined by many factors such as the genetic factors,
related to the number and type of nucleotide substitutions and the number of mutations required for a virus to acquire
full  resistance  to  the  drug  [56].  Another  factor  involved  in  the  resistance  to  DAAs is  determined  by  the  fitness  of
resistant virus populations, which is independent of the level of resistance conferred by RAMs [58].
Once resistance is acquired, a high risk of treatment failure occurs.
Sometimes, in patients with suboptimal response to treatment, HCV variants with a different level of susceptibility
may exist  naturally  at  low levels  in  the  absence  of  drug,  promoting  resistance  to  direct  acting  antiviral  agents  and
treatment failure [59].
Relapse of HCV in patients who initially respond to DAA may be due to the replication of a residual variant that
remained below the limit of detection at the end of treatment. After relapse, viral sequencing may identify the virus
sequence  present  after  treatment,  but  sometimes  an  important  phenomenon  could  occur  after  relapse;  in  fact  it  is
possible that a viral population could evolve to wild type prior to sequencing after relapse, as it is not under selective
pressure at the time [56].
The viral variants following a treatment failure are resistant to one or several of the drugs administered [56].
In these not rare cases the viral trigger is even more difficult to suppress and it could play a pivotal role in the onset
of HCC. Indeed HCC risk was increased 17-fold in HCV-infected patients compared with HCV-negative controls and
in many of these cases, HCC patients might have had HCV detected by polymerase chain reaction testing of liver tissue
and/or serum, even if antibody to HCV (anti-HCV) was nondetectable [5]. A failure or relapse in HCV therapy may
have a decisive weight in favoring the development of HCC. To ensure effective treatment the HCV subtype should be
determined prior to therapy and resistance testing could be an important weapon to fight all  the detrimental effects
generated by virus escape and replication, which are the basis of HCC onset in HCV patients.
CONCLUSION
Future  studies  on this  phenomenon should report  data  from bigger  sample  size  with  a  longer  follow-up period.
Moreover, the distinct clinical characteristics of the patients, included in the studies should be uniform. For example,
Villani  et  al.  show that  Reig  et  al.  recruited  some patients  who were  treated  with  “non-curative”  practice,  such  as
chemoembolization, characterized by early recurrence tumor rates. This could explain the high rate of HCC recurrence
observed by the Spanish group [52].
All these results show that, in particular for those patients who experienced HCC, all patients should be followed,
both during and after DAAs therapy.
In conclusion, all data available do not seem to directly correlate DAAs therapy with HCC development in HCV
treated patients, although patients who experienced HCC showed a high rate of tumor recurrence.
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